Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


States Increase Scrutiny Of Consumer-Targeted Genetic Screening

This article was originally published in The Pink Sheet Daily

Executive Summary

In particular, state agencies are targeting genetic screening services promoted to consumers over the Internet.

You may also be interested in...

Would Expanded Lab-Test Regulation Overstep FDA’s Legal Limits?

Efforts to alter the way laboratory tests are regulated highlight the need to better define FDA's authority over certain medical products

FDA Genetic Test Oversight Is On The Rise, But How Far Can It Go?

It looks increasingly likely that FDA will play a larger role in genetic test oversight, though policymakers may soon have to decide just how much more the agency can and should do

Device Week, 14 January 2021 – FDA Commissioner News; Spotlight On COVID-19 Enforcement Issues

On this week’s podcast we talk about outgoing US FDA chief Stephen Hahn and the role he wants to play beyond 20 January, as an ex-commissioner. We also discuss the US enforcement landscape around COVID-19-related products and how it’s still taking shape.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts